287 related articles for article (PubMed ID: 27490690)
1. Intra-Animal Comparison between Three-dimensional Molecularly Targeted US and Three-dimensional Dynamic Contrast-enhanced US for Early Antiangiogenic Treatment Assessment in Colon Cancer.
Wang H; Lutz AM; Hristov D; Tian L; Willmann JK
Radiology; 2017 Feb; 282(2):443-452. PubMed ID: 27490690
[TBL] [Abstract][Full Text] [Related]
2. Three-dimensional Dynamic Contrast-enhanced US Imaging for Early Antiangiogenic Treatment Assessment in a Mouse Colon Cancer Model.
Wang H; Hristov D; Qin J; Tian L; Willmann JK
Radiology; 2015 Nov; 277(2):424-34. PubMed ID: 26020439
[TBL] [Abstract][Full Text] [Related]
3. Three-dimensional ultrasound molecular imaging of angiogenesis in colon cancer using a clinical matrix array ultrasound transducer.
Wang H; Kaneko OF; Tian L; Hristov D; Willmann JK
Invest Radiol; 2015 May; 50(5):322-9. PubMed ID: 25575176
[TBL] [Abstract][Full Text] [Related]
4. Contrast-Enhanced Ultrasound with VEGFR2-Targeted Microbubbles for Monitoring Regorafenib Therapy Effects in Experimental Colorectal Adenocarcinomas in Rats with DCE-MRI and Immunohistochemical Validation.
Eschbach RS; Clevert DA; Hirner-Eppeneder H; Ingrisch M; Moser M; Schuster J; Tadros D; Schneider M; Kazmierczak PM; Reiser M; Cyran CC
PLoS One; 2017; 12(1):e0169323. PubMed ID: 28060884
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetic Modeling of Targeted Ultrasound Contrast Agents for Quantitative Assessment of Anti-Angiogenic Therapy: a Longitudinal Case-Control Study in Colon Cancer.
Turco S; El Kaffas A; Zhou J; Lutz AM; Wijkstra H; Willmann JK; Mischi M
Mol Imaging Biol; 2019 Aug; 21(4):633-643. PubMed ID: 30225758
[TBL] [Abstract][Full Text] [Related]
6. Quantitative Three-Dimensional Dynamic Contrast-Enhanced Ultrasound Imaging: First-In-Human Pilot Study in Patients with Liver Metastases.
El Kaffas A; Sigrist RMS; Fisher G; Bachawal S; Liau J; Wang H; Karanany A; Durot I; Rosenberg J; Hristov D; Willmann JK
Theranostics; 2017; 7(15):3745-3758. PubMed ID: 29109773
[No Abstract] [Full Text] [Related]
7. Early prediction of tumor response to bevacizumab treatment in murine colon cancer models using three-dimensional dynamic contrast-enhanced ultrasound imaging.
Zhou J; Zhang H; Wang H; Lutz AM; El Kaffas A; Tian L; Hristov D; Willmann JK
Angiogenesis; 2017 Nov; 20(4):547-555. PubMed ID: 28721500
[TBL] [Abstract][Full Text] [Related]
8. US imaging of tumor angiogenesis with microbubbles targeted to vascular endothelial growth factor receptor type 2 in mice.
Willmann JK; Paulmurugan R; Chen K; Gheysens O; Rodriguez-Porcel M; Lutz AM; Chen IY; Chen X; Gambhir SS
Radiology; 2008 Feb; 246(2):508-18. PubMed ID: 18180339
[TBL] [Abstract][Full Text] [Related]
9. Antiangiogenic cancer therapy: monitoring with molecular US and a clinically translatable contrast agent (BR55).
Pysz MA; Foygel K; Rosenberg J; Gambhir SS; Schneider M; Willmann JK
Radiology; 2010 Aug; 256(2):519-27. PubMed ID: 20515975
[TBL] [Abstract][Full Text] [Related]
10. Dynamic contrast-enhanced micro-computed tomography correlates with 3-dimensional fluorescence ultramicroscopy in antiangiogenic therapy of breast cancer xenografts.
Pöschinger T; Renner A; Eisa F; Dobosz M; Strobel S; Weber TG; Brauweiler R; Kalender WA; Scheuer W
Invest Radiol; 2014 Jul; 49(7):445-56. PubMed ID: 24598441
[TBL] [Abstract][Full Text] [Related]
11. Squamous Cell Carcinoma Xenografts: Use of VEGFR2-targeted Microbubbles for Combined Functional and Molecular US to Monitor Antiangiogenic Therapy Effects.
Baetke SC; Rix A; Tranquart F; Schneider R; Lammers T; Kiessling F; Lederle W
Radiology; 2016 Feb; 278(2):430-40. PubMed ID: 26313618
[TBL] [Abstract][Full Text] [Related]
12. Tumor angiogenic marker expression levels during tumor growth: longitudinal assessment with molecularly targeted microbubbles and US imaging.
Deshpande N; Ren Y; Foygel K; Rosenberg J; Willmann JK
Radiology; 2011 Mar; 258(3):804-11. PubMed ID: 21339349
[TBL] [Abstract][Full Text] [Related]
13. Vascular endothelial growth factor receptor type 2-targeted contrast-enhanced US of pancreatic cancer neovasculature in a genetically engineered mouse model: potential for earlier detection.
Pysz MA; Machtaler SB; Seeley ES; Lee JJ; Brentnall TA; Rosenberg J; Tranquart F; Willmann JK
Radiology; 2015 Mar; 274(3):790-9. PubMed ID: 25322341
[TBL] [Abstract][Full Text] [Related]
14. Assessment of angiogenesis in rabbit orthotropic liver tumors using three-dimensional dynamic contrast-enhanced ultrasound compared with two-dimensional DCE-US.
Zheng Q; Zhang JC; Wang Z; Ruan SM; Li W; Pan FS; Chen LD; Zhang YC; Wu WX; Xie XY; Lu MD; Shan QY; Wang W
Jpn J Radiol; 2019 Oct; 37(10):701-709. PubMed ID: 31401722
[TBL] [Abstract][Full Text] [Related]
15. VEGFR2-Targeted Three-Dimensional Ultrasound Imaging Can Predict Responses to Antiangiogenic Therapy in Preclinical Models of Colon Cancer.
Zhou J; Wang H; Zhang H; Lutz AM; Tian L; Hristov D; Willmann JK
Cancer Res; 2016 Jul; 76(14):4081-9. PubMed ID: 27206846
[TBL] [Abstract][Full Text] [Related]
16. Relationship between retention of a vascular endothelial growth factor receptor 2 (VEGFR2)-targeted ultrasonographic contrast agent and the level of VEGFR2 expression in an in vivo breast cancer model.
Lee DJ; Lyshchik A; Huamani J; Hallahan DE; Fleischer AC
J Ultrasound Med; 2008 Jun; 27(6):855-66. PubMed ID: 18499845
[TBL] [Abstract][Full Text] [Related]
17. BR55: a lipopeptide-based VEGFR2-targeted ultrasound contrast agent for molecular imaging of angiogenesis.
Pochon S; Tardy I; Bussat P; Bettinger T; Brochot J; von Wronski M; Passantino L; Schneider M
Invest Radiol; 2010 Feb; 45(2):89-95. PubMed ID: 20027118
[TBL] [Abstract][Full Text] [Related]
18. Dual-targeted contrast agent for US assessment of tumor angiogenesis in vivo.
Willmann JK; Lutz AM; Paulmurugan R; Patel MR; Chu P; Rosenberg J; Gambhir SS
Radiology; 2008 Sep; 248(3):936-44. PubMed ID: 18710985
[TBL] [Abstract][Full Text] [Related]
19. Quantitative assessment of tumor blood flow in mice after treatment with different doses of an antiangiogenic agent with contrast-enhanced destruction-replenishment US.
Zhou JH; Cao LH; Liu JB; Zheng W; Liu M; Luo RZ; Han F; Li AH
Radiology; 2011 May; 259(2):406-13. PubMed ID: 21292869
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of high frequency ultrasound methods and contrast agents for characterising tumor response to anti-angiogenic treatment.
Rix A; Lederle W; Siepmann M; Fokong S; Behrendt FF; Bzyl J; Grouls C; Kiessling F; Palmowski M
Eur J Radiol; 2012 Oct; 81(10):2710-6. PubMed ID: 22093958
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
